Osteoarthritis and Cartilage · Apr 2025
Scientific paper describing RM-010 as a capsaicin controlled-release system for chronic knee osteoarthritis pain and listing Relevium-affiliated authors.
Platform injectable gel based therapeutic for osteoarthritis
Company research
Public company, workplace, funding, and market signals
Overview
Galway-based University of Galway spinout developing RM-010, a hydrogel-based, non-opioid treatment platform for chronic pain, with a lead focus on knee osteoarthritis.
Primary product
RM-010 injectable hydrogel for knee osteoarthritis pain relief
Founded
2019
Headquarters
Galway, Ireland
Team size
1-10
Industry
Pharmaceutical Manufacturing
Sub-industry
Biopharmaceuticals / chronic-pain therapeutics
Offices
Unit 203B, Business Innovation Centre, University of Galway, Upper Newcastle, Galway, H91 NY52, Ireland
Ireland
United States
Business model
proprietary biopharmaceutical R&D
grant-funded development
clinical-stage commercialization
Funding
Stage
pre-seed / grant-backed early clinical
Total raised
$5.3M
Latest round
Grant · Nov 2024
Latest amount
$4.8M
People & investors
Leadership
CEO & Co-Founder
Barry McDermott
CTO & Co-Founder
Martin O'Halloran
Scientific Advisor & Co-Founder
Damien Kelly
CFO
Commercialisation Advisor
Principal Scientist
Principal Scientist / Operations Lead
Kevin Behan
Senior Research Chemist
Simona Cacciapuoti
Development Chemist
Work & culture
Mission-driven and female-led; the company publicly emphasizes being innovative, courageous, resilient, committed, honest, and proactive.
Product & market
Pricing
Per-treatment reimbursed injectable therapy; public pricing is not finalized, but insurance is cited at about $770 per six-month treatment.
Differentiators
- —Designed to reduce the burning pain associated with standard capsaicin
- —Long-lasting, non-opioid pain relief
- —Hydrogel platform that can extend to other joints and chronic-pain indications
- —Physician-friendly intra-articular administration
Technology
hydrogel drug delivery
capsaicin-controlled release
intra-articular injection
TRPV1-targeted pain mechanism
biopolymer-based formulations
preclinical pain models
Customers
patients with knee osteoarthritis and chronic pain
orthopedic and pain clinicians
health systems and payers
Competitors
corticosteroid injections
oral NSAIDs
opioids
viscosupplement injections
other osteoarthritis pain-therapy developers
Scale & contact
Estimated revenue
≈$330k-$402k estimated annual revenue
Estimated monthly visits
977
Latest news
Irish Tech News · Nov 2024
Covers the government-backed funding award, the RestOAre project, and the University of Galway/HookeBio consortium.
Silicon Republic · Nov 2024
Reported the company won €4.6m from the Disruptive Technologies Innovation Fund for the RestOAre project and noted the earlier EIC support for its osteoarthritis program.
University of Galway · Nov 2024
Official university announcement confirming the €4.6m DTIF award, nine-person team, and the collaboration with University of Galway and HookeBio.
Business Post · Jun 2024
Reported that Relevium Medical planned to raise €10m for clinical trials, had raised about €3.4m to date, and expected to add staff and move toward manufacturing.
Jobs and careers at Relevium Medical
0 jobs at Relevium Medical
No open positions
Check back later for new openings